Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-Week results

Journal of Drugs in Dermatology

Volumn 13, Issue 2, 2014, Pages 154-160

  Berman, Brian ^a   Goldenberg, Gary ^b   Hanke, C William ^c   Tyring, Stephen K ^d   Werschler, Wm Philip ^e   Knudsen, Kim Mark ^f   Goncalves, Joana ^g   Larsson, Thomas ^f   Skov, Torsten ^f   Swanson, Neil ^h  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Laser and Skin Surgery Center of Indiana   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f LEO PHARMA A S   (Denmark)

^g LEO Pharma Inc   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; LIQUID NITROGEN;

ACTINIC KERATOSIS; AGED; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTICLE; BASAL CELL CARCINOMA; CONTROLLED STUDY; CRYOSURGERY; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; EYE INJURY; EYE IRRITATION; EYE SWELLING; FEMALE; FIELD STUDY; GASTROINTESTINAL DISEASE; GEL; HEADACHE; HEART DISEASE; HUMAN; INJURY; INTOXICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SKIN TIGHTNESS; SQUAMOUS CELL CARCINOMA; TACHYCARDIA; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; AGED; COMBINED MODALITY THERAPY; CRYOSURGERY; DERMATOLOGIC AGENTS; DITERPENES; DOUBLE-BLIND METHOD; FACE; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; KERATOSIS, ACTINIC; MALE; SCALP; TREATMENT OUTCOME;

EID: 84896353626     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Goldberg LH, Mamelak AJ. Review of actinic keratosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol. 2010;9:1125-1132.
2. Einspahr JG, Stratton SP, Bowden GT, et al. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol. 2002;41:269-285. (Pubitemid 34203664)
3. Babilas P, Landthaler M, Szeimies RM. [Actinic keratoses]. Hautarzt. 2003;54:551-560.
4. Memon AA, Tomenson JA, Bothwell J, et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154-1159. (Pubitemid 30418302)
5. The Lewin Group Inc. for the Society of Investigative Dermatology and The American Academy of Dermatology Association. The burden of skin diseases. Available at: http://www.lewin.com/~/media/Lewin/Site-Sections/Publications/ april2005skindisease.pdf. Accessed August 14, 2013.
6. Balkrishnan R, Cayce KA, Kulkarni AS, et al. Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatolog Treat. 2006;17:162-166. (Pubitemid 44147835)
7. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42:25-28.
8. Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol. 2004;43:638-642. (Pubitemid 39276288)
9. Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(Suppl 2):34-40. (Pubitemid 350179628)
10. Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol. 2012;11:1462-1467.
11. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008;7:669-673.
12. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006;5:133-139.
13. Tan JK, Thomas DR, Poulin Y, et al. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg. 2007;11:195-201.
14. Jorizzo JL, Markowitz O, Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010;9:1101-1108.
15. Serra-Guillen C, Nagore E, Hueso L, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol. 2012;66:e131-e137.
16. LEO Pharma. Picato® (ingenol mebutate) gel, 0.015%, 0.05%. Prescribing information. Available at: www.picato.com/-pdf/ PrescribingInformation.pdf. Accessed April 26, 2013.
17. Berman B. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. Clin Cosmet Investig Dermatol. 2012;5:111-122.
18. Keating GM. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis. Drugs. 2012;72:2397-2405.
19. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010-1019.
20. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64:2833-2839. (Pubitemid 38500622)
21. Stahlhut M, Bertelsen M, Hoyer-Hansen M, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol. 2012;11:1181-1192.
22. Hampson P, Kavanagh D, Smith E, et al. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother. 2008;57:1241-1251.
23. Lebwohl M, Shumack S, Gold LS, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013; 149:666-670.
24. TNS ICAP Healthcare. A Report on the Actinic Keratosis Market Landscape in Australia. Athens: TNS ICAP Healthcare. 2008.
25. TNS ICAP Healthcare. A Study of Australians With Actinic Keratosis. Athens: TNS ICAP Healthcare. 2008.
26. Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43:687-692. (Pubitemid 39276301)
27. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934-943.